Biocidal products must be phased off the GB market The active substance/product type combinations listed below are due to expire under the GB Biocidal Products Regulation (GB BPR) on the following dates: Iodine (CAS 7553-56-2 EC 231-442-4) in product types 1, 4 and 22
31 August 2025
n-Decanoic acid (decanoic acid) (CAS 334-48-5 EC 206-376-4) in product types 18 and 19
31 August 2025
n-Octanoic acid (octanoic acid) (CAS 124-07-2 EC 204-677-5) in product type 18
31 August 2025
Polyvinylpyrrolidone iodine (CAS 25655-41-8 EC 607-771-8) in product types 1, 4 and 22
31 August 2025 Once the approvals expire, the active substances will no longer be able to be used in biocidal products of the relevant product types in GB. In addition, articles treated with such products will no longer be able to be placed on the market in GB. Submit a notification by the deadline to keep active substances in the GB Review Programme HSE has published open invitations to provide an opportunity for a person, company or task force/consortium to notify an intention to take up or take over the role of participant in the GB Review Programme for the following active substance/product type combinations. Â Anyone wishing to support one of the active substance/product type combinations listed below in GB will need to submit a notification to HSE by the following deadlines: Reaction products of 5,5-dimethylhydantoin, 5-ethyl-5-methylhydantoin with bromine and chlorine (DCDMH) (CAS N/A EC N/A) in product type 11
15 February 2025
Reaction products of 5,5-dimethylhydantoin, 5-ethyl-5-methylhydantoin with chlorine (DCEMH) (CAS 89415-87-2 EC 401-570-7) in product type 11
15 February 2025 If a notification to take over the role of participant is not received, these active substance/product type combinations will be subject to a GB non-approval decision. This means the active substances will no longer be able to be used in biocidal products of the relevant product type in GB. Â In addition, articles treated with such products will no longer be able to be placed on the market in GB. HSE will provide separate updates on these where relevant. Â If you are aware of any disproportionate negative impacts that are likely to arise from the non-approval of any of the active substance/product type combinations listed above, please contact us. | 